1. MARKETS
  2. SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
  3. INDUSTRY : BIOTECHNOLOGY
  4. CONTINEUM THERAPEUTICS INC. - ORDINARY SHARES - CLASS A

Contineum Therapeutics Inc. - Ordinary Shares - Class A

XNAS: CTNM

Download real time

3.50 -0.06 (-1.69%)

Near 52W Low of $3.42

72,428 XNAS Volume

XNAS 27 May, 2025 5:30 PM (EDT)

Watchlist

Portfolio

Share
4S
16W
1O
2T
90.6

Market Cap

Below industry Median
-1.8

PE TTM

Negative PE TTM
0

PEG TTM

0.5

Price to Book

Below industry Median
0.0

Beta 1Year

Very Low volatility
Board Meeting
The next board meeting for Contineum Therapeutics Inc. - Ordinary Shares - Class A is on 30 May 2025 for the purpose of Contineum Therapeutics Inc First Quarter Earnings Results for 2025 See details


Insider Trading disclosures for Contineum Therapeutics Inc. - Ordinary Shares - Class A

The latest disclosure was made by Tim Watkins in Contineum Therapeutics Inc. - Ordinary Shares - Class A where a trade of 260,000 Stock Option (right to buy) done was reported to US exchanges on April 28, 2025.

Insider trading is the trading of a company’s securities by individuals with access to confidential or material non-public information about the company. A company is required to report trading by corporate officers, directors, or other company members with significant access to privileged information to the Securities and Exchange Commission (SEC).

Client Name Client Category Action Reported to Exchange Quantity Post Transaction Holding Traded % Avg. Price Value Security Type
Tim Watkins CMO & Head of Development Grant, award, or other acquisition of securities at price $ 0.00 per share. 28 Apr 2025 260,000 260,000 - - Stock Option (right to buy)
Tim Watkins CMO & Head of Development Grant, award, or other acquisition of securities at price $ 0.00 per share. 28 Apr 2025 26,000 26,000 - - Stock Option (right to buy)
Diego Miralles Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 14 Mar 2025 29,500 29,500 - - Stock Option (right to buy)
Stephen L. Huhn CMO & Sr VP, Clinical Dev. 31 Jan 2025 110,000 110,000 - - Stock Option (right to buy)
Daniel S. Lorrain Chief Scientific Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 31 Jan 2025 3,700 3,700 - - Stock Option (right to buy)
Daniel S. Lorrain Chief Scientific Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 31 Jan 2025 110,000 110,000 - - Stock Option (right to buy)
Carmine Stengone Director, CEO and President Grant, award, or other acquisition of securities at price $ 0.00 per share. 31 Jan 2025 300,000 300,000 - - Stock Option (right to buy)
Peter T. Slover Chief Financial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 31 Jan 2025 110,000 110,000 - - Stock Option (right to buy)
S. Lorrain Daniel Chief Scientific Officer Sale of securities on an exchange or to another person at price $ 16.02 per share. 25 Nov 2024 1,010 168,562 - 16.0 16,177 Class A Common Stock
Daniel S. Lorrain Chief Scientific Officer Sale of securities on an exchange or to another person at price $ 16.37 per share. 18 Nov 2024 6,091 169,671 - 16.4 99,733 Class A Common Stock
Daniel S. Lorrain Chief Scientific Officer Sale of securities on an exchange or to another person at price $ 17.05 per share. 18 Nov 2024 99 169,572 - 17.1 1,688 Class A Common Stock
Stephen L. Huhn CMO & Sr VP, Clinical Dev. 13 Aug 2024 12,800 161,394 - - Stock Option (right to buy)
Stephen L. Huhn CMO & Sr VP, Clinical Dev. 13 Aug 2024 12,800 12,800 - 1.0 12,928 Class A Common Stock
Sarah Boyce Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 24 Jun 2024 29,500 29,500 - - Stock Option (right to buy)
Stephen L. Huhn CMO & Sr VP, Clinical Dev. 24 May 2024 100,000 100,000 - - Stock Option (right to buy)
Daniel S. Lorrain Chief Scientific Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 24 May 2024 100,000 100,000 - - Stock Option (right to buy)
Daniel S. Lorrain Chief Scientific Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 24 May 2024 3,700 3,700 - - Stock Option (right to buy)
Carmine Stengone Director, CEO and President Grant, award, or other acquisition of securities at price $ 0.00 per share. 24 May 2024 285,000 285,000 - - Stock Option (right to buy)
Evert B. Schimmelpennink Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 24 May 2024 29,500 29,500 - - Stock Option (right to buy)
Lori Lyons-Williams Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 24 May 2024 29,500 29,500 - - Stock Option (right to buy)
Olivia C. Ware Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 24 May 2024 3,700 3,700 - - Stock Option (right to buy)
Troy A. Ignelzi Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 24 May 2024 6,350 6,350 - - Stock Option (right to buy)
Peter T. Slover Chief Financial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 24 May 2024 100,000 100,000 - - Stock Option (right to buy)
Troy A. Ignelzi Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 20 May 2024 23,150 23,150 - - Stock Option (right to buy)
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc  
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges
View All The Insider Trades disclosures
Screeners based on Insider Trading and SAST parameters